The effectiveness ofdantrolene sodium in controlling tetanic spasms was evaluated in 21 children (aged 4 days-13 years) with tetanus.-These dantrolenetreated patients were compared with an historical control group of 26 children previously treated for tetanus by traditional means at the same institution. The groups were'comparable in terms 'of age, other treatments, and severity of disease. All patients received standard treatments for tetanus, including sedatives, antibiotics, and tetanus-immune globulin. Patients in the dantrolene-treated group also received dantrolene, either intravenously (Dantrium® Intravenous) or orally, in divided doses totalling 4-6 mg/kg/day. Mortality was 73% (neonates 83%, non-neonates 50%) in the control group, compared with 33% (neonates 50%, non-neonates 0%) in the dantrolene-treated group. Dantrolene did not cause additional respiratory depression when administered alone or in combination with other drugs routinely used to treat tetanus. In this study, the use of dantrolene with traditional conservative therapy significantly reduced mortality from tetanus.
Introduction
Tetanus is relatively uncommon in North America, in the USSR, and in most of Europe. Nevertheless, 300 000 to 500 000 cases occur worldwide each year, with a mortality rate of approximately 45%. Tetanus neonatorum remains a major cause of infant mortality in developing countries'. Dantrolene sodium is a direct-acting skeletal muscle relaxant which acts beyond the neuromuscular junction at the level of the sarcoplasmic reticulum. Dantrolene has been shown to be effective in treating malignant hyperthermia and in controlling spasticity resulting from upper motor neuron disorders such as cerebral palsy, multiple sclerosis, spinal cord injury, and stroke. The myorelaxant effect of dantrolene has also been found to be effective in reducing the spasms associated with tetanus2'3.
The purpose of the present study was to further investigate the efficacy of dantrolene in the treatment of tetanus. Specifically, an attempt was made to assess the effect of dantrolene on the frequency and severity of tetanic spasms and on the range of motion of various joints, to evaluate its effect on respiratory function, and to compare mortality rates for tetanus patients treated with dantrolene with rates for similar patients previously treated without dantrolene.
Methods
Patients: The group of patients eligible under the study protocol to receive dantrolene therapy consisted of children (age range newborn-15 years) admitted to the Hospital DIF del Nino-in Culiacan, Sinaloa, Mexico, with a primary diagnosis of tetanus. All patients exhibited localized or generalized muscle spasms as'demonstrated by trismus or opisthotonus.
The clinical course ofpatients treated with dantrolene was compared with that of an historical control group of similar patients (age range neonates-14 years) who did not receive dantrolene therapy in their treatment for tetanus at the same institution between November 1980 and January 1982.
Treatment: Upon admission, patients in the dantrolene group were examined and the severity of tetanus was graded according to the classification system of Patel and Joag4. Complete blood count, urinalysis, and blood biochemical profiles were performed.
Patients were fasted for 24-48 hours, and parenteral fluids were administered, as required. Central venous lines were installed in neonates and in older patients in serious condition; other patients had intravenous lines established in a superficial vein. Human tetanus-immune globulin was administered intramuscularly in a single dose -of 500 iu to neonates or 3000-6000 iu to non-neonates. Crystalline penicillin G sodium (50 000 iu/kg body weight) was administered intravenously every 12 hours to newborns for 10 days. Penicillin G procaine 80 000 iu/day or penicillin G benzathine 200 000-60 000 iu/day was given intramuscularly to non-neonates. Jaundiced patients were sedated with phenobarbital (3mg/kg/ day) in three divided intravenous doses; other patients were sedated with diazepam (0.3 mg/kg) administered intravenously every 4, 6, or 8 hours. Patients were isolated from light and noise, stimulated as little as possible, and watched closely.
Oxygen was administered at a rate of 2 
In this open-label study, dantrolene was supplied as the commercially available intravenous preparation (Dantrium®' Intravenous [20 mg dantrolene sodium and 3000mg mannitol per vial]) and as an oral suspension (5 mg dantrolene sodium/ml). Sterile water for injection (without a bacteriostatic agent) was used to reconstitute the intravenous preparation to a concentration of 0.33 mg/ml and a pH of approximately 9.5. Dantrolene treatment was initiated immediately after hospital admission and establishment of a diagnosis of tetanus. The intravenous formulation was given. either through a central venous line or a superficial vein, and the suspension was administered orally or through a nasogastric tube. Generally, the intraven'ous formu-0141-0768/86/ 050277-05/$02.00/0 ) 1986
The Royal Society of Medicine lation was given at first, at a dose of 1 mg/kg/hour for 3 hours. Succeeding doses of 1 mg/kg were given at 4-, 6-or 8-hour intervals, depending on the degree of improvement or control of spasm. After the acute stage of the disease had passed, treatment was changed to the oral suspension. Dantrolene therapy was continued for a maximum of 35 days.
Patients for whom dantrolene did not provide sufficient relaxation received pancuronium and respiratory assistance. Two 'Baby Bird' intermittent positive pressure respirators were available for use in children weighing up to 10 kg.
All baseline evaluations, except laboratory tests and Patel-Joag severity grading, were repeated daily for the duration of the study. Laboratory tests, including liver function tests, were repeated on the sixteenth and last days of dantrolene therapy. Treatment regimens used for patients in the control group were similar to that used for patients in the study group, except that dantrolene was not administered. Patients were fasted for 24 hours and later fed through a nasogastric tube. Parenteral fluids were given as required. Control patients received penicillin, human or equine tetanus-immune globulin, and muscle relaxants (diazepam, methocarbamol) at response dosage. Newborns with respiratory disorders, such as laryngeal spasm, cyanosis, and apnoea, received pancuronium and respiratory assistance. This historical control group is a subset of a group of 30 tetanus patients described in a previous paper5.
Statistical methods: Because this study was not randomized, statistical comparison of dantrolenetreated patients with retrospective control patients is not strictly appropriate. However, 95% confidence intervals for estimates of mortality in dantrolenetreated and control patients can be compared under the assumption that the patients in the two groups differed only in the type of treatment they received (standard anti-tetanus procedures v. standard antitetanus procedures plus dantrolene). Confidence intervals for estimates of mortality rates were obtained using a chart for proportions found in Beyer6. A simple binomial model (survival/death) was assumed.
The two groups were compared on the basis of demographic variables, severity of illness, need for respiratory assistance, duration of illness, length of hospital stay, and mortality.
Results
Twenty-four children, aged 4 days to 13 years, were treated for tetanus with dantrolene. Three patients were not included in the analysis because ofprotocol violations. Twenty-six children previously treated for tetanus fulfilled the criteria for inclusion and served as historical controls. The demographic characteristics of the 21 dantrolene-treated children and the 26 historical controls were comparable ( Table 1 ). All children were mestizos from socioeconomically deprived families, and nearly all were from remote, mountainous areas where medical services, including immunization for tetanus, were non-existent. Age distribution was almost identical in the two groups. The preponderance of neonates in the study population is typical of tetanus incidence in developing countries1. The percentage of males in the dantrolene group (52%) was slightly lower than that in the control group (62%). Table 2 summarizes baseline clinical information obtained upon patient admission to the hospital. The control and dantrolene groups differed only slightly in baseline measures of severity. A similar proportion of patients was given one of the two highest severity grades, although more children in the control group received a grade of V than in the dantrolene group. The control group included a slightly higher percentage of patients with a Cole's period (time from the first symptom of tetanus to the first generalized spasm) of 48 hours or less and a somewhat higher percentage of patients with a temperature greater than or equal to 380C. All neonates in both groups were given a severity grade of IV or V.
Eight dantrolene-treated and 9 control patients required respiratory assistance. The effectiveness of the respirators was hampered by recurrent problems with uneven gas pressure, occasional unavailability of oxygen, and lack of equipment for monitoring the adequacy of alveolar ventilation. As such, the respirators were used principally as a last resort, when neonates were in danger of suffocation from Not all patients in each age group received both formulations. If a patient did not receive a formulation, a value of 0 was assigned when mean values for time were calculated. However, only the doses for those patients taking a formulation were used in calculating the mean dose.
laryngospasm and chest muscle fixation. All 9 children in the control group who received respiratory assistance died while on the respirator or shortly after its removal. Of the 8 dantrolene-treated children who received respiratory assistance, 6 died. Duration of illness and length of hospital stay are presented in Table 3 . Among survivors, duration of illness was comparable in the two groups, while length of hospital stay was slightly shorter in control patients. Non-surviving patients in the control group were in the hospital for an average of 7+1 days. In contrast, non-surviving neonates in the dantrolene group survived almost twice as long (13 + 3 days).
Concomitant conditions included omphalitis in 6 dantrolene-treated and 8 control patients; hyperbilirubinaemia in 4 dantrolene-treated and one control patient; and conjunctivitis in 3 dantrolenetreated and 4 control patients. Other conditions noted in a few patients included amoebiasis in the control group and pulmonary conditions, ascariasis, septicaemia, hypocalcaemia, duodenal obstruction, cardiac and renal insufficiency, and cellulitis in the dantrolene group. The greater number of concomitant illnesses noted in the dantrolene group may reflect improved record-keeping during the course of the study. Table 3 also shows mortality. The mortality in the control group was 19/26, or 73% (95% confidence interval of 53-89%), whereas mortality in the dantrolene-treated group was 7/21, or 33% (95% confidence interval of 14-57%). A significant difference in the mortality rates of the two groups is indicated by the negligible degree of overlap of the confidence intervals for these estimates.
The cause of death for all non-survivors in the con-trol group was respiratory arrest leading to cardiac arrest. Cause of death for non-survivors among the dantrolene-treated patients included pulmonary bleeding (3/7), respiratory insufficiency (2/7), cardiac and renal insufficiency (1/7), and bronchoaspiration (1/7).
Mean dosages of dantrolene administered to surviving children in the dantrolene group are shown in Table 4 . The average dose of the intravenous formulation given to children up to 5 years old was close to the maximum dose of 6 mg/kg/day allowed under the protocol. Dosages of the intravenous formulation and oral suspension were lower in older children and reflect the lower doses needed to control spasms in these patients. Table 4 also shows that the surviving neonates required 8 + 2 days of therapy with the intravenous formulation before reaching the end of the acute stage and beginning to receive the oral suspension. Surviving children aged 1-13 years required only 1-2 days of treatment with the intravenous formulation before they began receiving the oral suspension.
Clinical variables monitored during dantrolene treatment could not be compared with similar data from control patients because these data were not consistently available from the hospital records of retrospective cases. On the average, for dantrolenetreated survivors, spasms were relieved in 12+2 days, free range of neck flexion was attained in 15 + 3 days, and trismus was relieved in 16+ 3 days.
Relief of spasms in response to dantrolene therapy in the 7 patients aged 1-13 years was excellent, and all 7 survived. Use of the oral suspension in these patients resulted in the most dramatic improvement noted during the study. Those children able to communicate verbally commented on reduction in pain following dantrolene treatment. Response to treatment in patients up to one year old was good-to-excellent in 9 and poor in 5. All but 2 of the children with good-to-excellent response survived. In the 2 children who died, death was not attributed to tetanus but to other causes (bronchoaspiration, sepsis). All 5 neonates with poor treatment response died.
Dantrolene, alone or in combination with diazepam, barbiturates, methocarbamol, or other concomitant medications, did not appear to have any additional depressant effect on respiratory function in any patient. No adverse reactions to the drug were noted. The only unexplained abnormal laboratory findings to occur during dantrolene therapy were 4 cases of eosinophilia (2 in neonates and 2 in older children). The appearance of this phenomenon in the older children may have been due to concomitant parasitic infections.
Discussion
Worldwide, the mortality rate for tetanus is roughly 45%1 Mortality from tetanus neonatorum is even higher, about 60%7. Since the mortality rate from tetanus is influenced heavily by socioeconomic and natural conditions8, it is even higher in underdeveloped countries. The overall mortality rate in the dantrolene group was 33%, significantly lower than that in the control group, where the rate was 73%, a figure consistent with rates in developing countries as reported in the literature.
When one considers only non-neonates, the difference in mortality rates between the two groups is especially striking, although the difference is not statistically significant because of the small number of cases involved. In these older children, mortality in the control group was 50% whereas in the dantrolene group it was 0%. Among neonates, mortality was 83% in the control group compared with 50% in the dantrolene group. Although the mortality rate for dantrolene-treated neonates seems high, it is substantially lower than the rate of 90% associated with conservatively treated cases in developing countries9. The difference in mortality rates between the control and dantrolene groups suggests that dantrolene treatment was effective in reducing tetanic spasms without suppressing respiratory function and, as a result, improved survival in these gravely ill children.
Several investigators have reported reduced mortality from tetanus with the use of intermittent positive pressure ventilation, neuromuscular blockade, continuous assessment of alveolar ventilation, and intensive nursing care. Smythe et al.9, in South Africa, reported that replacement of traditional conservative therapy with this approach lowered mortality from tetanus neonatorum from over 90% to 21%. Adams et al.10, in the USA, also reported successful management using similar methods, attributing improvement in survival to increasing sophistication in the intensive care management of neonates, including biochemical monitoring and continuous assessment of the adequacy of alveolar ventilation. Unfortunately, such highly developed technology is available to only a very small percentage of tetanus patients, and the expense and expertise involved in its implementation will preclude its use in the developing countries for many years. Merely having intermittent positive pressure ventilation equipment is not sufficient to lower mortality, as evidenced by the disappointing results achieved with its use at our study site. Uneven gas pressure, difficulty in maintaining neuromuscular blockade, and inability to monitor alveolar ventilation and cardiac function resulted in high mortality among respirator-treated neonates in both groups.
A large majority of tetanus cases worldwide are treated conservatively with muscle relaxants, sedatives, and nursing care. Diazepam has been used widely to control spasms; however, when large doses are given in an attempt to control severe spasms, respiratory depression may result. In our study, addition ofdantrolene to a treatment regimen including diazepam during the acute stage of the disease reduced spasms without compromising respiratory or cardiac function. Administration of dantrolene during the convalescent stage, when sedation was no longer necessary or desired, provided relief from spasms without CNS-depressant effects. Since most tetanus patients receive conservative treatment, the addition of an agent such as dantrolene, which would achieve better control of tetanic spasms without causing respiratory depression, would be of great value.
Non-neonates required intravenous treatment for a relatively short period, responding well to the doses administered. In contrast, some neonates, even when given doses of approximately 6 mg/kg/day of intravenous dantrolene, still succumbed to respiratory arrest due to laryngospasm and chest muscle fixation. In an unpublished study (data on file at Norwich Eaton Pharmaceuticals, Inc), the dose of oral suspension necessary to control spasms was considerably higher than 12 mg/kg/day. Thus, it is possible that the doses given neonates in our study were not large enough. The dose of the intravenous formulation is limited by the large amount of fluid needed for reconstitution. However, use of the oral suspension does not require the concomitant administration of large volumes of fluid and therefore does not pose the risk of fluid overload. Administration of the oral suspension via nasogastric tube during the acute stage of the disease would permit treatment with a higher dose, and thus might improve response. That the 7 non-surviving neonates treated with dantrolene lived almost twice as long as non-surviving patients in the control group suggests that dantrolene treatment prolonged their lives. Administration of higher doses of dantrolene, either as the intravenous formulation plus the oral suspension or as the oral suspension alone, should be considered when response to treatment is inadequate and respiratory arrest is an imminent threat.
In this study, mortality from tetanus was significantly reduced by the administration of dantrolene intravenous or dantrolene oral suspension, or both, when combined with traditional conservative therapy. Dantrolene did not cause additional respiratory depression at doses up to 6 mg/kg/day, when administered to children receiving concomitant diazepam, methocarbamol, barbiturates, or other drugs used to treat the disease. In developing countries, where the incidence of tetanus is high and where health care professionals must rely on traditional conservative therapy because the equipment needed for more sophisticated approaches is not available, the use of dantrolene in the management of tetanus would be especially valuable.
